Theriva Biologics Selected as Finalist in International Competition for Merck KGaA's EMEA Advance Biotech Grant
Theriva Biologics (NYSE American: TOVX) has been selected as one of five finalists for Merck KGaA's EMEA Advance Biotech Grant. The company will present its VCN-01 therapy, currently in Phase 2b clinical trials for first-line metastatic pancreatic cancer, at BIO-Europe 2024 in Stockholm. Dr. Manel Cascalló will showcase the therapy's novel mechanisms and manufacturing process on November 4, 2024. The grant program offers winners financial support and commercialization guidance, including consultation with M Ventures. The winner will be announced following presentations from all five finalists.
Theriva Biologics (NYSE American: TOVX) è stata selezionata come uno dei cinque finalisti per il Merck KGaA's EMEA Advance Biotech Grant. L'azienda presenterà la sua terapia VCN-01, attualmente in fase di sperimentazione clinica di Fase 2b per il cancro pancreatico metastatico di prima linea, al BIO-Europe 2024 a Stoccolma. Il Dr. Manel Cascalló mostrerà i meccanismi innovativi e il processo di produzione della terapia il 4 novembre 2024. Il programma di sovvenzione offre supporto finanziario e orientamento alla commercializzazione, inclusa la consulenza con M Ventures. Il vincitore sarà annunciato dopo le presentazioni di tutti e cinque i finalisti.
Theriva Biologics (NYSE American: TOVX) ha sido seleccionada como uno de los cinco finalistas para la Merck KGaA's EMEA Advance Biotech Grant. La compañía presentará su terapia VCN-01, actualmente en ensayos clínicos de fase 2b para el cáncer de páncreas metastásico en primera línea, en BIO-Europe 2024 en Estocolmo. El Dr. Manel Cascalló exhibirá los mecanismos novedosos y el proceso de fabricación de la terapia el 4 de noviembre de 2024. El programa de subvenciones ofrece a los ganadores apoyo financiero y orientación sobre comercialización, incluida la consulta con M Ventures. El ganador se anunciará después de las presentaciones de los cinco finalistas.
Theriva Biologics (NYSE American: TOVX)는 Merck KGaA의 EMEA Advance Biotech Grant의 다섯 최종 후보 중 하나로 선정되었습니다. 이 회사는 현재 2b상 임상 시험이 진행 중인 1차 전이성 췌장암에 대한 VCN-01 치료법을 스톡홀름에서 열리는 BIO-Europe 2024에서 발표할 예정입니다. Manel Cascalló 박사는 2024년 11월 4일에 치료법의 혁신적인 메커니즘과 제조 과정을 선보일 것입니다. 이 지원 프로그램은 수상자에게 재정 지원과 상업화 지침을 제공하며, M Ventures와의 상담도 포함됩니다. 수상자는 다섯 최종 후보의 발표 후에 발표될 것입니다.
Theriva Biologics (NYSE American: TOVX) a été sélectionnée comme l'un des cinq finalistes pour le Merck KGaA's EMEA Advance Biotech Grant. L'entreprise présentera sa thérapie VCN-01, actuellement en essais cliniques de phase 2b pour le cancer du pancréas métastatique de première ligne, lors de BIO-Europe 2024 à Stockholm. Le Dr. Manel Cascalló présentera les mécanismes novateurs et le processus de fabrication de la thérapie le 4 novembre 2024. Le programme de subventions offre aux gagnants un soutien financier et des conseils sur la commercialisation, y compris des consultations avec M Ventures. Le gagnant sera annoncé après les présentations des cinq finalistes.
Theriva Biologics (NYSE American: TOVX) wurde als einer von fünf Finalisten für das Merck KGaA's EMEA Advance Biotech Grant ausgewählt. Das Unternehmen wird seine VCN-01 Therapie, die sich derzeit in klinischen Phase-2b-Studien für fortgeschrittenes metastasiertes Pankreaskrebs befindet, auf der BIO-Europe 2024 in Stockholm präsentieren. Dr. Manel Cascalló wird am 4. November 2024 die neuartigen Mechanismen und den Herstellungsprozess der Therapie vorstellen. Das Stipendienprogramm bietet den Gewinnern finanzielle Unterstützung und Beratung zur Commercialisierung, einschließlich Konsultationen mit M Ventures. Der Gewinner wird nach den Präsentationen aller fünf Finalisten bekannt gegeben.
- Selected as finalist for Merck KGaA's EMEA Advance Biotech Grant
- Potential to receive financial support and commercialization guidance if selected as winner
- None.
Winner to be Presented at BIO-Europe 2024 in Stockholm, Sweden
ROCKVILLE, Md., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced selection as one of five finalists for Merck KGaA's EMEA Advance Biotech Grant. Finalists for the grant will present to a six-judge panel from Merck’s Emerging Biotech group during BIO Europe 2024 in Stockholm, Sweden.
Manel Cascalló, PhD., General Director - EU Subsidiary, Theriva Biologics, will present an overview of VCN-01, currently being studied in a Phase 2b clinical trial in first-line metastatic pancreatic cancer in combination with standard-of-care chemotherapy. Dr Cascalló will highlight VCN-01’s novel mechanisms of action and Theriva’s internal capabilities to develop its manufacturing process in his presentation on Monday, November 4, 2024 from 15:20-16:40 CET/CEST (GMT+2).
Merck KGaA’s EMEA Advance Biotech Grant Program celebrates standout emerging biotech companies, and winners receive financial support and guidance on navigating their path to commercialization, including consultation with M Ventures. After multiple rounds of dynamic competition involving diverse biotech companies and technologies, the five selected finalists, will pitch their breakthroughs to Merck KGaA representatives and the overall BIO-Europe audience. The winner will be announced following the five presentations.
About Theriva™ Biologics, Inc.
Theriva™ Biologics (NYSE American: TOVX), is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. The Company is advancing a new oncolytic adenovirus platform designed for intravenous (IV), intravitreal and antitumoral delivery to trigger tumor cell death, improve access of co-administered cancer therapies to the tumor, and promote a robust and sustained anti-tumor response by the patient’s immune system. The Company’s lead candidates are: (1) VCN-01, an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a significant physical and immunosuppressive barrier to cancer treatment; (2) SYN-004 (ribaxamase) which is designed to degrade certain commonly used IV beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage, thereby limiting overgrowth of pathogenic organisms such as VRE (vancomycin resistant Enterococci) and reducing the incidence and severity of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients; and (3) SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases. For more information, please visit Theriva Biologics’ website at www.therivabio.com.
Forward-Looking Statement
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases forward-looking statements can be identified by terminology such as “may,” “should,” “potential,” “continue,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” and similar expressions, and include statements regarding presenting an overview of VCN-01to a six-judge panel from Merck’s Emerging Biotech group during BIO Europe 2024 in Stockholm, Sweden and highlighting VCN-01’s novel mechanisms of action and Theriva’s internal capabilities to develop its manufacturing process. These forward-looking statements are based on management’s expectations and assumptions as of the date of this press release and are subject to a number of risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the Company’s ability to reach clinical milestones when anticipated, the Company’s product candidates demonstrating safety and effectiveness, as well as results that are consistent with prior results, the Company’s ability to complete clinical trials on time and achieve the desired results and benefits, continuing clinical trial enrollment as expected; the Company’s ability to obtain regulatory approval for commercialization of product candidates or to comply with ongoing regulatory requirements, regulatory limitations relating to the Company’s ability to promote or commercialize their product candidates for the specific indications, acceptance of product candidates in the marketplace and the successful development, marketing or sale of the Company’s products, developments by competitors that render such products obsolete or non-competitive, the Company’s ability to maintain license agreements, the continued maintenance and growth of the Company’s patent estate, the ability to continue to remain well financed and other factors described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 and its other filings with the SEC, including subsequent periodic reports on Forms 10-Q and current reports on Form 8-K. The information in this release is provided only as of the date of this release, and Theriva Biologics undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.
For further information, please contact:
Investor Relations:
Chris Calabrese
LifeSci Advisors, LLC
ccalabrese@lifesciadvisors.com
917-680-5608
FAQ
When will Theriva Biologics (TOVX) present at BIO-Europe 2024?
What is Theriva Biologics (TOVX) presenting at the Merck KGaA grant competition?